ライフサイエンスコーパス: autonomic neuropathy

1 s relatively spared in experimental diabetic autonomic neuropathy.

2 ibodies and had idiopathic or paraneoplastic autonomic neuropathy.

3 logic markers of various forms of autoimmune autonomic neuropathy.

4 educed HRV identifies diabetic patients with autonomic neuropathy.

5 ood flow would be impaired in diabetics with autonomic neuropathy.

6 with long-standing diabetes and established autonomic neuropathy.

7 abetic distal symmetrical polyneuropathy and autonomic neuropathy.

8 evidence of definite and 10 (31%) had early autonomic neuropathy.

9 tential pathogenetic mechanisms for diabetic autonomic neuropathy.

10 31.3% Child B, and 60% Child C had definite autonomic neuropathy.

11 in patients with advanced liver disease and autonomic neuropathy.

12 t, and parasymN dysfunction is a hallmark of autonomic neuropathy.

13 pastic paraplegia and hereditary sensory and autonomic neuropathy.

14 core for cardiovascular disease, and cardiac autonomic neuropathy.

15 ia, cardiovascular disease risk, and cardiac autonomic neuropathy.

16 lternate phenotype of hereditary sensory and autonomic neuropathy.

17 en genetically linked with human sensory and autonomic neuropathy.

18 astating genetic disease featuring a bladder autonomic neuropathy.

19 arrhythmias associated with diabetic cardiac autonomic neuropathy.

20 eta as a new therapeutic target for diabetic autonomic neuropathy.

21 Half had autonomic neuropathy.

22 l dysautonomia (FD), a recessive sensory and autonomic neuropathy.

23 ulin treatment, metabolic abnormalities, and autonomic neuropathy.

24 nglionic antibody likely mediates autoimmune autonomic neuropathy.

25 tribute to the development of human diabetic autonomic neuropathy.

26 in the pathogenesis of experimental diabetic autonomic neuropathy.

27 Moreover, in hereditary sensory and autonomic neuropathies.

28 iabetic large and small fiber peripheral and autonomic neuropathies.

29 neuronal dysfunction and loss in the sensory/autonomic neuropathies.

30 nesis, pathophysiology and treatment of some autonomic neuropathies.

31 ), and arterial stiffness and cardiovascular autonomic neuropathy (24 [1.8%] vs 13 [1.0%]; p=0.015).

32 mmon signs were peripheral neuropathy (47%), autonomic neuropathy (31%), cerebellar ataxia (26%), sub

33 inating neuropathy (2.8; 1.6-5.1; P = .001), autonomic neuropathy (4.2; 1.4-12.3; P = .009), and mono

34 6 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent), in 6 of 67 patients w

35 stural tachycardia syndrome, 211; peripheral autonomic neuropathy, 463; myalgic encephalomyelitis/chr

36 Hereditary sensory and autonomic neuropathy 9 (HSAN9) is a rare fatal neurologi

37 ic gastrointestinal dysmotility, or diabetic autonomic neuropathy (9 percent), and in none of 44 pati

38 ients (13 female, 5 male) who had autoimmune autonomic neuropathy (AAN) and ganglionic acetylcholine

39 Autoimmune autonomic neuropathy (AAN) is an acquired, often severe,

40 There is evidence of an autonomic neuropathy affecting the lower-extremity blood

41 Sensory and autonomic neuropathy affects the majority of type II dia

42 Autonomic neuropathy (AN) is seen in both alcohol-induce

43 It is unknown whether autonomic neuropathy (AN) may contribute to these mechan

44 ave implications for both long-term diabetic autonomic neuropathies and insulin-induced hypoglycemia,

45 es patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders f

46 Diabetic autonomic neuropathy and endothelial dysfunction impair

47 The link between cardiac autonomic neuropathy and risk of cardiovascular disease

48 ch could elucidate the link between diabetic autonomic neuropathy and stroke.

49 renal, or liver involvement or peripheral or autonomic neuropathy and treatment naive.

50 nerve abnormalities, frequent optic atrophy, autonomic neuropathy and upper and lower motor neurone s

51 axia, 2 Lambert-Eaton myasthenic syndrome, 1 autonomic neuropathy, and 1 motor neuropathy).

52 omia (FD) is a severe hereditary sensory and autonomic neuropathy, and all patients with FD have a sp

53 treatment of Parkinson's disease-associated autonomic neuropathy, and antioxidant therapies have bee

54 processes, including hepatitis C infection, autonomic neuropathy, and drug side effects, that can re

55 y aid in early detection of both sensory and autonomic neuropathy, and perhaps in the case of patient

56 The autonomic neuropathies are a group of disorders in which

57 Hereditary sensory and autonomic neuropathies are a group of phenotypically rel

58 The hereditary motor, sensory and autonomic neuropathies are a heterogeneous group of neur

59 Some autonomic neuropathies are treatable.

60 ion, axonal sensory-motor polyneuropathy and autonomic neuropathy are commonly seen in patients with

61 Cardiac autonomic neuropathy arises in the presence of uremia an

62 pathy, peripheral neuropathy, cardiovascular autonomic neuropathy, arterial stiffness, and hypertensi

63 Finally, autonomic neuropathy as a complication of severe liver d

64 s' CNFL correlated with the severity of both autonomic neuropathy assessed by the Compound Autonomic

65 In addition to the autonomic neuropathy associated with long-standing diabe

66 abetic distal symmetrical polyneuropathy and autonomic neuropathy but that the clinical role of ARIs

67 Autonomic neuropathies can also occur as a result of amy

68 rmine the association between cardiovascular autonomic neuropathy (CAN) and indices of left ventricle

69 y on the prevalence and incidence of cardiac autonomic neuropathy (CAN) in former DCCT intensive and

70 Cardiac autonomic neuropathy (CAN) is a significant cause of mor

71 Cardiovascular autonomic neuropathy (CAN) is associated with increased

72 s studies have suggested that cardiovascular autonomic neuropathy (CAN) may predict rapid kidney func

73 It has been suggested that cardiac autonomic neuropathy (CAN) might indicate those who are

74 ripheral neuropathy (DPN) and cardiovascular autonomic neuropathy (CAN).

75 t and progression of diabetic cardiovascular autonomic neuropathy (CAN).

76 myloidosis characterized by sensorimotor and autonomic neuropathy, cardiac conduction defects, and in

77 ly progressive gastrointestinal symptoms and autonomic neuropathy caused by autosomal dominant, hered

78 Familial dysautonomia (FD) is a sensory and autonomic neuropathy caused by mutations in elongator co

79 When evaluating a patient with subacute autonomic neuropathy, certain autoantibodies are importa

80 mmon member of a group of congenital sensory/autonomic neuropathies characterized by widespread senso

81 ary motor neuropathy, hereditary sensory and autonomic neuropathy, complicated hereditary spastic par

82 Diabetic autonomic neuropathy (DAN) has been invoked as a cause o

83 Diabetic autonomic neuropathy (DAN) may impact the BM, because th

84 The classical diabetic autonomic neuropathy (DAN) that eventually occurs in the

85 In subjects with diabetic autonomic neuropathy (DAN), distal left ventricular (LV)

86 d morbidity and mortality in severe diabetic autonomic neuropathy (DAN).

87 duals with long-standing type I diabetes and autonomic neuropathy has not been assessed, nor has it b

88 ity to pain (CIP) and hereditary sensory and autonomic neuropathies (HSAN) are clinically and genetic

89 Hereditary sensory and autonomic neuropathy (HSAN) types IA and IC (IA/C) are c

90 acts distinctly from hereditary sensory and autonomic neuropathy (HSAN)-causing SPTLC2 variants by c

91 nerves are involved, hereditary sensory and autonomic neuropathy (HSAN).

92 ost prevalent form of hereditary sensory and autonomic neuropathy (HSAN).

93 Hereditary sensory and autonomic neuropathies (HSANs) encompass a group of gene

94 of gene mutations of hereditary sensory and autonomic neuropathies I, III and IV could lead to more

95 he gene mutations for hereditary sensory and autonomic neuropathies I, III, and IV are now known and

96 hemical sympathectomy in mice resulted in BM autonomic neuropathy, impaired Lin(-)cKit(+)Sca1(+) (LKS

97 he neuropathological hallmark of sympathetic autonomic neuropathy in diabetic rats, increased 9- to 1

98 opathologic hallmark of diabetic sympathetic autonomic neuropathy in human and several insulinopenic

99 Diabetes is the most common cause of autonomic neuropathy in more developed countries.

100 neuritic dystrophy, the hallmark of diabetic autonomic neuropathy in mouse prevertebral sympathetic g

101 In conclusion, autonomic neuropathy in the BM impairs stem cell mobiliz

102 t an exclusively autoimmune pathogenesis for autonomic neuropathy in this model.

103 Autonomic neuropathy is a major component of familial am

104 Idiopathic autonomic neuropathy is a severe, subacute disorder with

105 Our findings indicate autonomic neuropathy is an early and prominent deficit i

106 Diabetic autonomic neuropathy is associated with an impaired vaso

107 Autonomic neuropathy is generally believed to be respons

108 nal degeneration characteristic for diabetic autonomic neuropathy is minor.

109 Although autonomic neuropathy is recognized as an independent ris

110 pathetic nerve fibres in human patients when autonomic neuropathy is suspected.

111 A limited autonomic neuropathy may underlie some unusual clinical

112 ility (AGID) is a limited form of autoimmune autonomic neuropathy occurring idiopathically or in a pa

113 patients with liver disease had evidence of autonomic neuropathy; of these, 12 (36%) had evidence of

114 haracterised by a progressive peripheral and autonomic neuropathy often with associated cardiac failu

115 hey are elevated, such as hereditary sensory autonomic neuropathies or diabetes.

116 elation was observed between the severity of autonomic neuropathy or the duration of diabetes and the

117 Autonomic neuropathy predisposes patients to ventricular

118 progressive distal symmetric polyneuropathy, autonomic neuropathy, radiculo-plexopathies, and mononeu

119 Diabetic autonomic neuropathy results in significant morbidity an

120 a (FD), a devastating hereditary sensory and autonomic neuropathy, results from an intronic mutation

121 ng cholinergic systems, including autoimmune autonomic neuropathy, seizures, dementia, and movement d

122 king improvement in the severity of diabetic autonomic neuropathy shown with IGF-I treatment in these

123 inflammation, advanced glycation endpoints, autonomic neuropathy, sleep-disordered breathing, and ge

124 ptoms were more prominent than were motor or autonomic neuropathy symptoms.

125 much greater risk of developing a painful or autonomic neuropathy than those individuals with no chan

126 It is indistinguishable from the subacute autonomic neuropathy that may accompany lung cancer or o

127 lial dysautonomia (FD) is a rare sensory and autonomic neuropathy that results from a mutation in the

128 ith idiopathic and paraneoplastic autoimmune autonomic neuropathy, the severity parallels serum level

129 f a larger disease process, such as diabetic autonomic neuropathy, traumatic brain injury, and spinal

130 Hereditary sensory and autonomic neuropathy type 1 (HSAN1) causes sensory loss

131 ants cause peripheral hereditary sensory and autonomic neuropathy type 1 (HSAN1) due to the synthesis

132 Hereditary sensory and autonomic neuropathy type 1 (HSAN1) is characterized by

133 concentrations cause hereditary sensory and autonomic neuropathy type 1 (HSAN1), an axonal neuropath

134 PT are known to cause hereditary sensory and autonomic neuropathy type 1 (HSAN1), we examined 10 addi

135 (SPTLC1), which cause hereditary sensory and autonomic neuropathy type 1 (HSAN1).

136 mic the mutations seen in hereditary sensory autonomic neuropathy type 1 as well as a third mutant N1

137 ations in human SPT cause hereditary sensory autonomic neuropathy type 1, a disease characterized by

138 l diseases, including hereditary sensory and autonomic neuropathy type 1A (HSAN1A), GM3 synthase defi

139 clinical spectrum for hereditary sensory and autonomic neuropathy type 1E (HSAN1E) and a potential pa

140 Hereditary sensory and autonomic neuropathy type I (HSAN I) is the most frequen

141 ause an adult-onset, hereditary sensory, and autonomic neuropathy type I (HSAN1).

142 ical disease known as hereditary sensory and autonomic neuropathy type I (HSAN1).

143 Hereditary sensory and autonomic neuropathy type III (HSAN III) is a rare neuro

144 Individuals with hereditary sensory and autonomic neuropathy type III (HSAN III), also known as

145 amilial dysautonomia (hereditary sensory and autonomic neuropathy type III), we found that the techni

146 Hereditary sensory and autonomic neuropathy type III, or familial dysautonomia

147 ered in patients with Hereditary Sensory and Autonomic Neuropathy type V (HSAN V), caused by the 661C

148 h factor (NGF) causes Hereditary Sensory and Autonomic Neuropathy type V, a rare disease characterize

149 monogenic disorders: Hereditary Sensory and Autonomic Neuropathy type VI (caused by a loss of DST-a)

150 tions in SPTLC1 cause hereditary sensory and autonomic neuropathy (type I) (HSAN1), an adult onset, a

151 d with autosomal-dominant hereditary sensory autonomic neuropathy, type 1A, by disrupting an essentia

152 our hypothesis, we evaluated the presence of autonomic neuropathy using a battery of tests in 33 pati

153 an in vivo streptozotocin model of diabetic autonomic neuropathy using an unbiased counting method t

154 wth factor I (IGF-I) on diabetic sympathetic autonomic neuropathy was examined in an experimental str

155 ensorimotor) neuropathy was found in 71% and autonomic neuropathy was found in 48% of the patients.

156 A diagnosis of idiopathic autonomic neuropathy was made.

157 To address the pathogenesis of diabetic autonomic neuropathy, we have examined the sympathetic n

158 nly dangerous as contributors to sensory and autonomic neuropathies when elevated by inherited SPT mu

159 subsequently were found to have sensorimotor autonomic neuropathy, whereas 2 others had subclinical a

160 r and microvascular complications, including autonomic neuropathy, which disrupts gut motility.

161 he areas of diabetic amyotrophy and diabetic autonomic neuropathy will also be reviewed.

162 There are several familial autonomic neuropathies with autosomal dominant, autosoma

163 tion are likely to have a high prevalence of autonomic neuropathy with an associated increase in mort

164 al dominant diseases: hereditary sensory and autonomic neuropathy with dementia and hearing loss type

165 ration in one form of hereditary sensory and autonomic neuropathy with dementia and hearing loss.

166 This is the first report of an acute autonomic neuropathy with documented EBV infection in CS

167 be a valuable model of diabetic sympathetic autonomic neuropathy with unambiguous, rapidly developin